Select Recent Publications

  1. Shafagati N, Stuver R, Boussi L, Koh MJ, Park A, Bain P, Foss FM, Shen c, Jain S. Comparative efficacy and tolerability of novel agents versus chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis. Blood Adv. 2022; DOI: Link. PMID: 35816645.
  2. Koh MJ, Merrill MH, Koh MJ, Stuver R, Alonso CD, Foss FM, Mayor AM, Gill JS,Epeldegui M, Cachay E, Thorne JE, Silverberg MJ, Horberg MA, Atlhoff KN, Nijhawan AE, McGinnis KA, Lee JS, Rabkin CS, Napravnik S, Li J, Castilho JL, Shen C, Jain S. Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas. Blood Adv. 2022; 6(5):1420-1431. PubMed Central PMCID: PMC8905704.
  3. Jain S, Van Scoyk A, Morgan EA, Matthews A, Stevenson K, Newton G, Powers F, Autio A, Louissaint A   Jr, Pontini G, Aster JC, Luscinskas FW, Weinstock DM. Targeted inhibition of CD47-SIRP alpha requires Fc-FcGR interactions to maximize activity in T-cell lymphomas. Blood. 2019;134(17):1430-1440. PubMed Central PMCID: PMC31383641.
  4. Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S. Single agents vs. combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. Am J Hematol. 2019; 94(6):641-649. PubMed Central PMCID: PMC30896890.
  5. Jain S, Washington A, Leaf RK, Bhargava P, Clark RA, Kupper TS, Stroopinsky D, Pyzer A, Cole L, Nahas M, Apel A, Rosenblatt J, Arnason J, Kufe D, Avigan D. Decitabine priming enhances Mucin 1 inhibition mediated disruption of redox hemostasis in cutaneous T-cell lymphoma. Mol Cancer Ther. 2017; 16(10):2304-2314. PubMed Central PMCID: PMC28729399.
  6. Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll   MD, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015; 126(3):354-62.  PubMed Central PMCID: PMC26048911.
  7. Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O’Connor OA. Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clin Cancer Res. 2015; 21(9):2096-106. PubMed Central PMCID: PMC25677697.

click to enlarge: